Show simple item record

Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma

dc.contributor.authorUysal, Mujdat
dc.contributor.authorDogru-Abbasoglu, Semra
dc.contributor.authorVural, Pervin
dc.contributor.authorBingul, Ilknur
dc.contributor.authorCil, Esra
dc.date.accessioned2021-03-04T09:30:07Z
dc.date.available2021-03-04T09:30:07Z
dc.date.issued2017
dc.identifier.citationBingul I., Vural P., Dogru-Abbasoglu S., Cil E., Uysal M., "Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma", JOURNAL OF CLINICAL LABORATORY ANALYSIS, cilt.31, sa.6, 2017
dc.identifier.issn0887-8013
dc.identifier.otherav_6895ed76-17ca-4d1d-97b8-56a57e5908d4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/72477
dc.identifier.urihttps://doi.org/10.1002/jcla.22110
dc.description.abstractBackgroundPapillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Vascular endothelial growth factor (VEGF) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T-460C, and A-2578C) and PTC susceptibility.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectTIBBİ LABORATUVAR TEKNOLOJİSİ
dc.titleVascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL LABORATORY ANALYSIS
dc.contributor.departmentIstanbul Sisli Hamidiye Etfal Training & Research Hospital , ,
dc.identifier.volume31
dc.identifier.issue6
dc.contributor.firstauthorID247252


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record